Sanofi and GSK recently finalised and signed an Advanced purchase agreement with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine, once the vaccine is approved.
The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.
This final agreement confirms the announcement made on July 31 by both companies and marks a key milestone in protecting European populations against COVID-19.
The contract will allow the purchase of a vaccine against COVID-19 for all Member States of the EU, which may donate reserved doses to lower- and middle-income countries.
The EU will provide upfront funding to support the scale-up of Sanofi and GSK manufacturing capabilities on European soil.
The antigen and final vaccine doses will be manufactured in European countries, leveraging Sanofi and GSK’s industrial sites in Belgium, Italy, Germany and France.
